CL2009001082A1 - Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86. - Google Patents

Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86.

Info

Publication number
CL2009001082A1
CL2009001082A1 CL2009001082A CL2009001082A CL2009001082A1 CL 2009001082 A1 CL2009001082 A1 CL 2009001082A1 CL 2009001082 A CL2009001082 A CL 2009001082A CL 2009001082 A CL2009001082 A CL 2009001082A CL 2009001082 A1 CL2009001082 A1 CL 2009001082A1
Authority
CL
Chile
Prior art keywords
binds
administering
ctla4
molecule
undifferentiated arthritis
Prior art date
Application number
CL2009001082A
Other languages
English (en)
Inventor
Michael Corbo
George Vratsanos
Jean-Claude Becker
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41264941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001082(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2009001082A1 publication Critical patent/CL2009001082A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Abstract

Procedimiento para tratar artritis indiferenciada que comprende administrar una molécula de ctla4 que se une a cd80 y/o cd86.
CL2009001082A 2008-05-05 2009-05-05 Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86. CL2009001082A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (1)

Publication Number Publication Date
CL2009001082A1 true CL2009001082A1 (es) 2010-02-12

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001082A CL2009001082A1 (es) 2008-05-05 2009-05-05 Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86.

Country Status (25)

Country Link
US (3) US7915222B2 (es)
EP (2) EP2891665A1 (es)
JP (1) JP2011522795A (es)
KR (1) KR20110014180A (es)
CN (1) CN102037010A (es)
AR (1) AR071672A1 (es)
AU (1) AU2009244448B2 (es)
BR (1) BRPI0912249A2 (es)
CA (1) CA2723698C (es)
CL (1) CL2009001082A1 (es)
DK (1) DK2279206T3 (es)
EA (1) EA201001749A1 (es)
ES (1) ES2539840T3 (es)
HK (1) HK1208230A1 (es)
HR (1) HRP20150552T1 (es)
HU (1) HUE025256T2 (es)
IL (1) IL208691A (es)
MX (1) MX2010011503A (es)
NZ (1) NZ589020A (es)
PL (1) PL2279206T3 (es)
PT (1) PT2279206E (es)
SI (1) SI2279206T1 (es)
TW (2) TWI454278B (es)
WO (1) WO2009137424A1 (es)
ZA (1) ZA201007914B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
JP6239517B2 (ja) * 2011-10-10 2017-11-29 メディミューン リミテッド 関節リウマチの治療法
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
US20150232558A1 (en) * 2012-10-30 2015-08-20 Emory University Stimulating bone formation by inhibition of cd28 co-stimulation
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
US20170042972A1 (en) * 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
KR100238712B1 (ko) 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
BR9405664A (pt) * 1993-01-21 1996-04-30 Univ Georgia Composto imunogenio processos para evitar a toxicose por festuca em um herbivoro para tratar a toxicose por festuca em um herbivoro anticorpo purificado lingagem de célula de hidridoma e anticorpo
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
PT892643E (pt) 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
KR20030007899A (ko) 2000-06-09 2003-01-23 브리스톨-마이어스스퀴브컴파니 림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HRP20030071B1 (hr) * 2000-07-03 2014-01-03 Bristol-Myers Squibb Company Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula
CA2436139A1 (en) 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
JP4541157B2 (ja) 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
DE60335024D1 (de) 2002-12-23 2010-12-30 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
AU2004264901B2 (en) 2003-08-04 2009-12-10 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble CTLA4 molecule
KR101280096B1 (ko) 2005-06-29 2013-06-28 컴퓨메딕스 리미티드 전도성 브리지를 포함하는 센서 어셈블리
CA2619429A1 (en) * 2005-08-22 2007-03-01 Incept, Llc Flared stents and apparatus and methods for making and using them
AU2006330922B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Compositions and methods for producing a composition
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
US7528111B2 (en) 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Also Published As

Publication number Publication date
NZ589020A (en) 2012-05-25
US20090280119A1 (en) 2009-11-12
EP2891665A1 (en) 2015-07-08
SI2279206T1 (sl) 2015-08-31
MX2010011503A (es) 2010-11-09
EP2279206B1 (en) 2015-04-22
ES2539840T3 (es) 2015-07-06
EP2279206A1 (en) 2011-02-02
TW200948381A (en) 2009-12-01
US20110142835A1 (en) 2011-06-16
US20130195865A1 (en) 2013-08-01
DK2279206T3 (en) 2015-07-27
HRP20150552T1 (hr) 2015-06-19
IL208691A (en) 2015-01-29
AR071672A1 (es) 2010-07-07
PL2279206T3 (pl) 2015-09-30
TWI454278B (zh) 2014-10-01
EP2279206A4 (en) 2011-05-25
HK1208230A1 (en) 2016-02-26
IL208691A0 (en) 2010-12-30
HK1148291A1 (en) 2011-09-02
CN102037010A (zh) 2011-04-27
AU2009244448B2 (en) 2014-07-31
US8435952B2 (en) 2013-05-07
AU2009244448A1 (en) 2009-11-12
EA201001749A1 (ru) 2011-06-30
US7915222B2 (en) 2011-03-29
US9012408B2 (en) 2015-04-21
HUE025256T2 (en) 2016-02-29
BRPI0912249A2 (pt) 2015-10-20
WO2009137424A1 (en) 2009-11-12
CA2723698A1 (en) 2009-11-12
JP2011522795A (ja) 2011-08-04
CA2723698C (en) 2018-03-06
TW201444575A (zh) 2014-12-01
PT2279206E (pt) 2015-07-27
KR20110014180A (ko) 2011-02-10
ZA201007914B (en) 2011-07-27

Similar Documents

Publication Publication Date Title
CL2009001082A1 (es) Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86.
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
BR112012015501A8 (pt) Processo de biodegradação e composição
MX2013008376A (es) Composiciones y metodos para el tratamiento de cancer.
BR112013016242A2 (pt) método de cimentação e, composição de cimentação
AU2016204248A1 (en) Boron-Containing Molecules
BR112014028644A2 (pt) Composições e métodos para modulação da expressão de atp2a2
CL2016000839A1 (es) Composiciones para modular la expresión de c9orf72.
BR112012016471A2 (pt) método para cimentação em uma formação subterrânea, e, composição de cimento
BR112016003127A2 (pt) “composições e métodos para modular rna”
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
WO2009111676A3 (en) Boron-containing small molecules as anti-inflammatory agents
BR112017008914A2 (pt) método para tratar câncer, composição e uso da composição
MX373763B (es) Uso de una composición de combinación de acamprosato y baclofeno de liberación sostenida, para el tratamiento de esclerosis lateral amiotrófica.
UA115652C2 (uk) Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
SG169988A1 (en) Rnai inhibition of alpha-enac expression
MX374826B (es) Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas.
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
CR20130138A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
MX361299B (es) Metodo para activar celulas auxiliares.
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину